Atara Biotherapeutics, Inc.
ATRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $6 | $17 | $14 | $25 |
| Short-Term Investments | $8 | $5 | $0 | $17 |
| Receivables | $2 | $0 | $9 | $1 |
| Inventory | $0 | $0 | $0 | $11 |
| Other Curr. Assets | $3 | $2 | $4 | $10 |
| Total Curr. Assets | $18 | $25 | $27 | $65 |
| Property Plant & Equip (Net) | $11 | $11 | $32 | $41 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $3 | $3 |
| Total NC Assets | $12 | $12 | $35 | $44 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $30 | $37 | $62 | $109 |
| Liabilities | – | – | – | – |
| Payables | $0 | $2 | $1 | $4 |
| Short-Term Debt | $12 | $2 | $28 | $14 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $1 | $2 | $16 | $95 |
| Other Curr. Liab. | $5 | $9 | $2 | $21 |
| Total Curr. Liab. | $18 | $15 | $48 | $135 |
| LT Debt | $47 | $15 | $27 | $30 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $42 | $43 | $42 |
| Total NC Liab. | $49 | $57 | $69 | $72 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $15 | $18 | $41 | $44 |
| Total Liabilities | $67 | $72 | $117 | $206 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$2,018 | -$2,014 | -$2,017 | -$2,055 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,982 | $1,979 | $1,961 | $1,957 |
| Total Equity | -$37 | -$35 | -$55 | -$97 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $30 | $37 | $62 | $109 |
| Net Debt | $53 | $1 | $41 | $19 |